Program
treprostinil
Also written as “Inhaled Treprostinil”, “treprostinil diethanolamine” and “Oral Treprostinil”.
Its studies are mostly in Pulmonary Arterial Hypertension · Hypertension, Pulmonary · Scleroderma, Systemic · Idiopathic Pulmonary Fibrosis · Chronic Limb-Threatening Ischemia, led by 5 companies.
Drug pageTreprostinil: every studyMany companies study it; this page follows only the 71 they lead. All 99 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| United Therapeuticsits history only | 625 open or running | phase 4since Apr 14, 2003 | Oct 18, 1999 | Nov 2027phase 3 · NCT05943535 |
| Liquidia Technologiesits history only | 64 open or running | phase 4since Aug 7, 2026 | Jan 3, 2018 | Feb 2027phase 2 · NCT07748000 |
| Mannkindits history only | 10 open or running | phase 1since Mar 1, 2018 | Mar 1, 2018 | none ahead |
| Pharmosa Biopharmits history only | 10 open or running | phase 1since Jul 23, 2019 | Jul 23, 2019 | none ahead |
| SciPharm SàRLits history only | 10 open or running | phase 3since Aug 12, 2011 | Aug 12, 2011 | none ahead |
Also a collaborator on its studies: PPD Development, LP, Nuventra, FGK Clinical Research and CVie Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Mar 20, 2008.
- Mar 4, 2019Phase 2 study in Pulmonary Arterial HypertensionLiquidia Technologies · NCT03884465 · 15 enrolled · France, Germany
- May 9, 2019Phase 1 study in Pulmonary Arterial HypertensionUnited Therapeutics · NCT03950739 · 51 enrolled · United States
- Jun 5, 2019Phase 3 study in Familial Primary Pulmonary HypertensionLiquidia Technologies · NCT03992755 · 92 enrolled · United States
- Jun 9, 2019Named treprostinilINNProposed as its International Nonproprietary Name in WHO's List 121
- Jul 23, 2019Pharmosa Biopharm’s first study: phase 1 study in Pulmonary Arterial HypertensionNew to Pharmosa BiopharmPharmosa Biopharm · NCT04041648 · 52 enrolled · United States
- Jan 12, 2021Phase 3 study in Idiopathic Pulmonary FibrosisUnited Therapeutics · NCT04708782 · 598 enrolled · United States, Canada, Chile
- May 20, 2021Phase 3 study in Idiopathic Pulmonary FibrosisUnited Therapeutics · NCT04905693 · 1,850 planned · United States, Argentina, Australia and more
- Jan 10, 2022Phase 4 study in Pulmonary Arterial HypertensionUnited Therapeutics · NCT05203510 · 52 enrolled · United States
- Feb 15, 2022Phase 3 study in Idiopathic Pulmonary FibrosisUnited Therapeutics · NCT05255991 · 597 enrolled · Argentina, Australia, Belgium and more
- Jul 5, 2023Phase 3 study in Lung Diseases, InterstitialUnited Therapeutics · NCT05943535 · 698 planned · United States, Argentina, Australia and more
- Dec 11, 2025Phase 3 study in Hypertension, PulmonaryLiquidia Technologies · NCT07285655 · 344 planned · United States, Australia, Austria and more
- Jul 31, 2026Phase 2 study in Scleroderma, SystemicLiquidia Technologies · NCT07748000 · 75 planned
- Aug 7, 2026Phase 4 study in Pulmonary Arterial HypertensionLiquidia Technologies · NCT07759804 · 20 planned · United States
- Oct 19, 2026Phase 2 study in Hypertension, PulmonaryUnited Therapeutics · NCT07923591 · 40 planned · United States
- Oct 19, 2026Phase 3 study in Hypertension, PulmonaryUnited Therapeutics · NCT07923526 · 400 planned · United States
Ahead
- Feb 2027Primary completion: phase 2 study in Scleroderma, SystemicLiquidia Technologies · NCT07748000
- May 2027Primary completion: phase 4 study in Pulmonary Arterial HypertensionLiquidia Technologies · NCT07759804
- Nov 2027Primary completion: phase 3 study in Lung Diseases, InterstitialUnited Therapeutics · NCT05943535
- May 2028Primary completion: phase 2 study in Hypertension, PulmonaryUnited Therapeutics · NCT07923591
TargetBeta
“Prostanoid IP receptor agonist; Prostanoid IP receptor agonist; Prostanoid IP receptor agonist”ChEMBL 37, by rule
Other programs on PTGIR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| selexipagrule | Johnson & Johnson | phase 4 | 23 |
Studies
The newest 60 of 71 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07923591Hypertension, Pulmonary · United States | 2 | Not yet recruiting | United Therapeutics | May 2028 | 40 |
| NCT07923526Hypertension, Pulmonary · United States | 3 | Not yet recruiting | United Therapeutics | Sep 2034 | 400 |
| NCT07759804Pulmonary Arterial Hypertension · United States | 4 | Recruiting | Liquidia Technologies | May 2027 | 20 |
| NCT07748000Scleroderma, Systemic | 2 | Not yet recruiting | Liquidia Technologies | Feb 2027 | 75 |
| NCT07285655Hypertension, Pulmonary · United States, Australia, Austria and more | 3 | Recruiting | Liquidia Technologies | Jul 2029 | 344 |
| NCT05943535Lung Diseases, Interstitial · United States, Argentina, Australia and more | 3 | Recruiting | United Therapeutics | Nov 2027 | 698 |
| NCT05255991Idiopathic Pulmonary Fibrosis · Argentina, Australia, Belgium and more | 3 | Completed | United Therapeutics | Jun 30, 2025 | 597 |
| NCT05203510Pulmonary Arterial Hypertension · United States | 4 | Active, not recruiting | United Therapeutics | Apr 30, 2026 | 52 |
| NCT04905693Idiopathic Pulmonary Fibrosis · United States, Argentina, Australia and more | 3 | By invitation | United Therapeutics | Dec 2029 | 1,850 |
| NCT04708782Idiopathic Pulmonary Fibrosis · United States, Canada, Chile | 3 | Completed | United Therapeutics | Feb 2, 2026 | 598 |
| NCT04041648Pulmonary Arterial Hypertension · United States | 1 | Completed | Pharmosa Biopharm | Sep 20, 2019 | 52 |
| NCT03992755Familial Primary Pulmonary Hypertension · United States | 3 | Active, not recruiting | Liquidia Technologies | May 31, 2025 | 92 |
| NCT03950739Pulmonary Arterial Hypertension · United States | 1 | Completed | United Therapeutics | Aug 22, 2023 | 51 |
| NCT03884465Pulmonary Arterial Hypertension · France, Germany | 2 | Terminated | Liquidia Technologies | Dec 23, 2020 | 15 |
| NCT03794583Hypertension, Pulmonary · United States, Israel, Italy | 3 | Terminated | United Therapeutics | Nov 29, 2022 | 41 |
| NCT03496623Hypertension, Pulmonary · United States, Argentina, Israel and more | 3 | Terminated | United Therapeutics | Oct 13, 2022 | 188 |
| NCT03497689Pulmonary Arterial Hypertension · United States | 4 | Completed | United Therapeutics | May 11, 2022 | 36 |
| NCT03464864Pulmonary Arterial Hypertension · United States | 1 | Completed | Mannkind | Jun 5, 2018 | 36 |
| NCT03399604Familial Primary Pulmonary Hypertension · United States | 3 | Completed | Liquidia Technologies | May 6, 2019 | 121 |
| NCT03055221Pulmonary Arterial Hypertension | 4 | Completed | United Therapeutics | Feb 25, 2014 | 20 |
| NCT03043651Hypertension, Pulmonary · United States | 3 | Terminated | United Therapeutics | Mar 2, 2020 | 48 |
| NCT03055234Pulmonary Hypertension Associated With Sickle Cell Disease | 3 | Withdrawn | United Therapeutics | Dec 2021 | 0 |
| NCT03037580Hypertension, Pulmonary · United States | 3 | Terminated | United Therapeutics | Dec 3, 2019 | 84 |
| NCT03016468Pulmonary Arterial Hypertension | 2 | Withdrawn | United Therapeutics | Sep 2018 | 0 |
| NCT03012646Hypertension, Pulmonary | 2 | Withdrawn | United Therapeutics | Apr 2019 | 0 |
| NCT02999906Pulmonary Arterial Hypertension | 3 | Withdrawn | United Therapeutics | Dec 2021 | 0 |
| NCT02893995Pulmonary Arterial Hypertension · China | 4 | Withdrawn | United Therapeutics | Apr 2018 | 0 |
| NCT02882126Pulmonary Arterial Hypertension · China | 4 | Withdrawn | United Therapeutics | Jun 2021 | 0 |
| NCT02847260Pulmonary Arterial Hypertension | 4 | Completed | United Therapeutics | Mar 2014 | 39 |
| NCT02633293Hypertension, Pulmonary · United States, Puerto Rico | 3 | Terminated | United Therapeutics | Aug 1, 2021 | 243 |
| NCT02630316Hypertension, Pulmonary · United States, Puerto Rico | 3 | Completed | United Therapeutics | Dec 26, 2019 | 326 |
| NCT02603068Hypertension, Pulmonary · United States | 2 | Withdrawn | United Therapeutics | Apr 2018 | 0 |
| NCT02276872PAH · United States | 2 | Completed | United Therapeutics | Jul 20, 2017 | 32 |
| NCT02318758Healthy · United States | 1 | Completed | United Therapeutics | Oct 2014 | 32 |
| NCT02261883Persistent Fetal Circulation Syndrome · United States | 2 | Terminated | United Therapeutics | Sep 27, 2022 | 42 |
| NCT01934582Pulmonary Arterial Hypertension · United States | 3 | Completed | United Therapeutics | Nov 2013 | 13 |
| NCT01884038Reperfusion Injury · United States | 3 | Withdrawn | United Therapeutics | Jun 2010 | 0 |
| NCT01746485Healthy · United States | 1 | Completed | United Therapeutics | Jul 2012 | 19 |
| NCT01557660Pulmonary Arterial Hypertension | 3 | Withdrawn | United Therapeutics | Dec 2018 | 0 |
| NCT01557647Pulmonary Arterial Hypertension | 3 | Withdrawn | United Therapeutics | Dec 2015 | 0 |
| NCT01560637Pulmonary Arterial Hypertension · United States, Argentina, Australia and more | 3 | Completed | United Therapeutics | Aug 12, 2021 | 471 |
| NCT01560624Pulmonary Arterial Hypertension · United States, Argentina, Australia and more | 3 | Completed | United Therapeutics | Jun 24, 2018 | 690 |
| NCT01588405Pulmonary Arterial Hypertension · United States | 2 | Completed | United Therapeutics | Jul 2014 | 33 |
| NCT01477333Pulmonary Arterial Hypertension · United States | 2 | Completed | United Therapeutics | Nov 2013 | 18 |
| NCT01416636Non-operable Chronic Thromboembolic Pulmonary Hypertension · Austria, Czechia, Germany and more | 3 | Completed | SciPharm SàRL | Nov 2016 | 105 |
| NCT01172496Pulmonary Arterial Hypertension · United States | 1 | Completed | United Therapeutics | Aug 2010 | 24 |
| NCT01165476Pulmonary Arterial Hypertension · United States | 1 | Completed | United Therapeutics | Aug 2010 | 64 |
| NCT01153386Pulmonary Arterial Hypertension · United States | 1 | Completed | United Therapeutics | Aug 2010 | 36 |
| NCT01131845Pulmonary Arterial Hypertension · United States | 1 | Completed | United Therapeutics | Sep 2010 | 16 |
| NCT01104870Hypertension, Pulmonary · United States | 2 | Completed | United Therapeutics | Jan 2013 | 50 |
| NCT01027949Pulmonary Arterial Hypertension · United States, Australia, Austria and more | 3 | Completed | United Therapeutics | Feb 12, 2020 | 894 |
| NCT00963027Hypertension, Pulmonary · United States | 1 | Completed | United Therapeutics | Oct 2009 | 30 |
| NCT00963001Hypertension, Pulmonary · United States | 1 | Completed | United Therapeutics | Nov 2009 | 32 |
| NCT00887978Hypertension, Pulmonary · United States, Belgium, Canada and more | 3 | Completed | United Therapeutics | Jul 2011 | 310 |
| NCT00848939Scleroderma, Systemic · United States | 1 | Completed | United Therapeutics | Jan 2010 | 28 |
| NCT00848107Scleroderma, Systemic · United States, Canada, United Kingdom | 2 | Terminated | United Therapeutics | Sep 2011 | 115 |
| NCT00775463Scleroderma, Systemic · United States, Canada, United Kingdom | 2 | Completed | United Therapeutics | Mar 2011 | 148 |
| NCT00760916Hypertension, Pulmonary · United States, Australia, Mexico | 3 | Withdrawn | United Therapeutics | Jan 2009 | 0 |
| NCT00741819Pulmonary Arterial Hypertension · United States | 4 | Completed | United Therapeutics | Mar 2010 | 73 |
| NCT00643604Hypertension, Pulmonary · United States | 4 | Terminated | United Therapeutics | Jan 2010 | 7 |
How it is read
Names in the registry
- “Inhaled Treprostinil”, 7 entries
- “treprostinil diethanolamine”, 6 entries
- “Oral Treprostinil”, 5 entries
- “treprostinil sodium”, 5 entries
- “UT-15C SR”, 4 entries
Conditions, from the studies’ own filings
- Pulmonary Arterial Hypertension, 38 studies
- Hypertension, Pulmonary, 17 studies
- Scleroderma, Systemic, 4 studies
- Idiopathic Pulmonary Fibrosis, 3 studies
- Chronic Limb-Threatening Ischemia, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.